Design Therapeutics, Inc. - Common Stock, par value $0.0001 per share (DSGN) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2021 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.0001 per share
Symbol
DSGN on Nasdaq
Shares outstanding
57,148,979
Price per share
$9.39
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
38,119,020
Total reported value
$357,552,417
% of total 13F portfolios
0%
Share change
+3,292,284
Value change
+$35,421,791
Number of holders
116
Price from insider filings
$9.39
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Design Therapeutics, Inc. - Common Stock, par value $0.0001 per share (DSGN) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Point72 Asset Management, L.P. 9.4% +84% $50,443,118 +$22,810,986 5,372,004 +83% Point72 Asset Management, L.P. 31 Dec 2025
Light Irrevocable Trust #1 dated April 22, 2019 6.9% $16,257,665 3,834,355 Light Irrevocable Trust #1 dated April 22, 2019 31 Dec 2024
Star Irrevocable Trust #1 dated April 22, 2019 6.9% $16,257,665 3,834,355 Star Irrevocable Trust #1 dated April 22, 2019 31 Dec 2024
Logos Global Management LP 4.4% -22% $16,322,350 -$4,802,600 2,515,000 -23% Arsani William 14 Nov 2025

As of 31 Dec 2025, 116 institutional investors reported holding 38,119,020 shares of Design Therapeutics, Inc. - Common Stock, par value $0.0001 per share (DSGN). This represents 67% of the company’s total 57,148,979 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Design Therapeutics, Inc. - Common Stock, par value $0.0001 per share (DSGN) together control 60% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
SR One Capital Management, LP 11% 6,526,476 0% 8.7% $61,218,345
Point72 Asset Management, L.P. 9.4% 5,372,004 +61% 0.08% $50,389,398
Logos Global Management LP 4.4% 2,500,000 -32% 1.6% $23,450,000
BAKER BROS. ADVISORS LP 3.9% 2,233,099 +30% 0.12% $20,946,469
BlackRock, Inc. 3.7% 2,117,156 +3.6% 0% $19,858,924
VANGUARD GROUP INC 2.9% 1,630,910 +13% 0% $15,297,936
Vivo Capital, LLC 2.8% 1,612,903 0.98% $15,129,030
Almitas Capital LLC 2.7% 1,530,435 0% 3.2% $14,355,480
RA CAPITAL MANAGEMENT, L.P. 2.6% 1,461,381 +207% 0.14% $13,707,754
Driehaus Capital Management LLC 2.1% 1,179,817 +9.6% 0.08% $11,066,683
Woodline Partners LP 1.7% 944,039 +54% 0.03% $8,855,086
Kynam Capital Management, LP 1.4% 784,606 -24% 0.48% $7,359,604
FMR LLC 1.3% 771,268 +4.1% 0% $7,234,494
MORGAN STANLEY 1.2% 702,306 +299% 0% $6,587,630
GEODE CAPITAL MANAGEMENT, LLC 1.2% 679,590 -2.3% 0% $6,375,975
STATE STREET CORP 1.1% 647,636 +2.1% 0% $6,074,826
ACADIAN ASSET MANAGEMENT LLC 1.1% 612,768 -0.76% 0.01% $5,742,000
Frazier Life Sciences Management, L.P. 0.91% 521,000 -73% 0.13% $4,886,980
CITADEL ADVISORS LLC 0.8% 459,874 -17% 0% $4,313,618
D. E. Shaw & Co., Inc. 0.77% 438,894 +18% 0% $4,116,825
Invesco Ltd. 0.54% 305,757 +1996% 0% $2,868,000
DIMENSIONAL FUND ADVISORS LP 0.52% 297,921 +6.5% 0% $2,795,478
RENAISSANCE TECHNOLOGIES LLC 0.5% 287,100 +4.7% 0% $2,692,998
NORTHERN TRUST CORP 0.5% 286,572 -3.4% 0% $2,688,045
GOLDMAN SACHS GROUP INC 0.47% 270,654 +3.5% 0% $2,538,735

Institutional Holders of Design Therapeutics, Inc. - Common Stock, par value $0.0001 per share (DSGN) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 38,119,020 $357,552,417 +$35,421,791 $9.38 116
2025 Q3 34,492,564 $259,728,206 +$644,093 $7.53 94
2025 Q2 34,530,294 $116,365,282 +$265,374 $3.37 91
2025 Q1 34,459,430 $133,014,167 +$2,133,109 $3.86 95
2024 Q4 33,460,789 $206,451,772 +$9,368,489 $6.17 94
2024 Q3 32,032,058 $172,330,017 +$1,330,349 $5.38 98
2024 Q2 32,097,220 $107,523,187 +$4,413,890 $3.35 92
2024 Q1 30,700,544 $123,722,605 -$3,107,582 $4.03 88
2023 Q4 31,717,256 $84,046,693 -$1,847,569 $2.65 87
2023 Q3 32,867,255 $77,567,491 -$67,849,061 $2.36 84
2023 Q2 38,786,588 $244,358,163 +$738,881 $6.30 96
2023 Q1 38,691,853 $223,252,292 -$16,074,747 $5.77 94
2022 Q4 40,381,322 $414,296,202 -$600,847 $10.26 81
2022 Q3 39,933,593 $667,698,632 +$24,544,231 $16.72 76
2022 Q2 38,690,076 $541,665,132 +$9,157,438 $14.00 70
2022 Q1 37,990,461 $613,724,140 +$27,782,038 $16.15 62
2021 Q4 36,170,094 $773,127,906 +$50,180,616 $21.41 58
2021 Q3 28,281,317 $414,830,000 +$5,824,856 $14.69 52
2021 Q2 27,817,792 $545,865,000 +$37,059,194 $19.89 49
2021 Q1 25,762,953 $755,185,000 +$755,158,004 $29.90 43